Active Biotech To Present At The Jefferies 2013 Global Healthcare Conference

LUND, Sweden, Nov. 14, 2013 (GLOBE NEWSWIRE) --
Active Biotech (NASDAQ OMX NORDIC: ACTI) isscheduled to present at the Jefferies Global Healthcare Conference held November20-21, 2013 in London, UK. During the presentation, an update regarding ActiveBiotech's development programs will be provided.The presentation will include the laquinimod project, a novel oralimmunomodulatory drug primarily for the treatment of multiple sclerosis,licensed to Teva Pharmaceutical, the Phase III prostate cancer projecttasquinimod in co-development with Ipsen, as well as ANYARA, Active Biotech'snovel concept for tumor therapy of primarily renal cell cancer. Also, theproject with paquinimod (57-57) and the pre-clinical ISI project will bepresented.The audio and slide presentation will be webcasted live and can be accessed viathe Active Biotech web site. To access the live and replay presentations pleasego to - www.activebiotech.com.The presentation will take place on November 20, at 08:00 a.m. GMT (GreenwichMean Time) / 09:00 am Central European Time.For further information, please contact:Hans Kolam, CFOPhone: +46 (0)46 19 20 44E-mail: hans.kolam@activebiotech.comActive Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company withfocus on autoimmune/inflammatory diseases and cancer. In pivotal phase islaquinimod, an orally administered small molecule with unique immunomodulatoryproperties for the treatment of multiple sclerosis. Also tasquinimod for thetreatment of prostate cancer, with a unique mode of action, is in pivotal phase.In addition, laquinimod has concluded Phase II development for Crohn's andLupus. The company has two additional projects in clinical development, ANYARAprimarily for the treatment of renal cell cancer and the orally administeredcompound paquinimod (57-57) for systemic sclerosis. Please visitwww.activebiotech.com for more information.Active Biotech AB (Corp. Reg. No. 556223-9227)Box 724, SE-220 07 LundTel: +46 46 19 20 00Fax: +46 46 19 11 00Active Biotech is obligated to publish the information contained in this pressrelease in accordance with the Swedish Securities Market Act. This informationwas provided to the media for publication 8:30 a.m. CET on November 14, 2013.Active Biotech to Present at the Jefferies 2013 Global Healthcare Conf: http://hugin.info/1002/R/1742843/586064.pdf[HUG#1742843]

If you liked this article you might like

Jim Cramer -- FireEye and Other Cybersecurity Firms Are a Long-Term Play

Jim Cramer -- FireEye and Other Cybersecurity Firms Are a Long-Term Play

Jim Cramer Says FireEye a Cybersecurity Stock Worth Considering

Jim Cramer Says FireEye a Cybersecurity Stock Worth Considering

Consumer Data in Focus in Coming Week

Consumer Data in Focus in Coming Week

ActivIdentity Soars; Global Payments Slides

ActivIdentity Soars; Global Payments Slides

Stocks Fight Off Fannie, Freddie

Stocks Fight Off Fannie, Freddie